Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

BACKGROUND: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Parseghian, Christine M., Parikh, Nila U., Wu, Ji Yuan, Jiang, Zhi-Qin, Henderson, Laura, Tian, Feng, Pastor, Brice, Ychou, Marc, Raghav, Kanwal, Dasari, Arvind, Fogelman, David R., Katsiampoura, Anastasia D., Menter, David G., Wolff, Robert A., Eng, Cathy, Overman, Michael J., Thierry, Alain R., Gallick, Gary E., Kopetz, Scott
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540760/
https://ncbi.nlm.nih.gov/pubmed/28280091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3138
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares